Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)

被引：0
|
作者：
Moehler, M. [1 ]
Wyrwicz, L. [2 ]
Chen, C. [3 ]
Davenport, E. [4 ]
Wang, J. [4 ]
Nathani, R. [3 ]
Kondo, K. [3 ]
Elimova, E. [5 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] RTI Int, Res Triangle Pk, NC USA
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-10
引用
收藏
页码：S185 / S185
页数：1
相关论文
共 50 条
  • [31] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [32] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Cao, Xueqiong
    Zhang, Mingming
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Song, Xiaobing
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [33] Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).
    Van Cutsem, Eric
    Singh, Prianka
    Cleary, James M.
    Kelly, Ronan Joseph
    Moehler, Markus H.
    Kuzdzal, Jaroslaw
    Mendez, Guillermo
    Motoyama, Satoru
    Elimova, Elena
    Grootscholten, Cecile
    Sun Xiaowu
    Taylor, Fiona
    Lawrance, Rachael
    Padilla, Brad
    Moreno-Koehler, Alejandro
    Zhang, Jenny
    Blum, Steven, I
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Daniel Lin
    Hiep Nguyen
    Ruchit Shah
    Yao Qiao
    John Hartman
    Ryan Sugarman
    Gastric Cancer, 2023, 26 : 415 - 424
  • [35] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Lin, Daniel
    Nguyen, Hiep
    Shah, Ruchit
    Qiao, Yao
    Hartman, John
    Sugarman, Ryan
    GASTRIC CANCER, 2023, 26 (03) : 415 - 424
  • [36] Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
    Felip, E.
    Wang, C.
    Ciuleanu, T-E.
    Saylors, G.
    Tanaka, F.
    Chen, K-N.
    Ito, H.
    Girard, N.
    Lu, S.
    Provencio Pulla, M.
    Mitsudomi, T.
    Awad, M.
    Forde, P. M.
    Lawrance, R.
    Taylor, F.
    Worthy, G.
    Blum, S. I.
    Vo, L.
    Cai, J. L.
    Spicer, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S973 - S974
  • [37] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [38] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [39] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [40] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Jiang, Yuan
    Li, Yue
    Wang, Larry X. W.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
12345